Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle/Wittenberg, Ernst-Grube-Straße 40, 06120 Halle/Saale, Germany.
Department of Medicine Director, Oncology Research for the North Bronx Healthcare Network Albert Einstein college of Medicine New York, NY.
Eur J Pharmacol. 2014 Jan 5;722:197-202. doi: 10.1016/j.ejphar.2013.09.073. Epub 2013 Oct 21.
Over the past decades major improvements in the management of chemotherapy induced nausea and vomiting (CINV) were obtained. With the correct use of antiemetic drugs, CINV can be prevented in almost 70%, and even up to, 80% of patients. Treatment guidelines enable physicians to integrate the latest clinical research into their daily practice. The large volume of rapidly evolving clinical data has been summarised and incorporated into treatment recommendations by well-known and reliable institutions. These organisations include the Multinational Association of Supportive Care in Cancer (MASCC), the European Society of Medical Oncology (ESMO), the American Society for Clinical Oncology (ASCO), and National Comprehensive Cancer Network (NCCN). However, despite the availability of these guidelines, there is an emerging evidence that adherence to, and implementation of, treatment recommendations is less than optimal. This review will especially focus on the content of the current antiemetic guidelines and will address the important question of how these guidelines are implemented in routine practice.
在过去的几十年中，化疗引起的恶心和呕吐（CINV）的管理取得了重大进展。通过正确使用止吐药物，近 70%的患者甚至 80%的患者可以预防 CINV。治疗指南使医生能够将最新的临床研究纳入他们的日常实践中。大量快速发展的临床数据已经由知名可靠的机构进行了总结，并纳入了治疗建议中。这些组织包括癌症支持治疗多国协会（MASCC）、欧洲肿瘤内科学会（ESMO）、美国临床肿瘤学会（ASCO）和国家综合癌症网络（NCCN）。然而，尽管有这些指南，但有证据表明，对治疗建议的遵循和实施并不尽如人意。这篇综述将特别关注当前止吐指南的内容，并探讨这些指南在常规实践中的实施问题。
